orderly semaglutide Wellness Novo Nordisk's semaglutide shortage officially

A recent study suggests that women and older adults who use the weight-loss drug semaglutide could be more vulnerable to losing muscle

A key feature of the consensus is its endorsement of shared decision-making, taking into account patient goals, preferences, access, and affordability

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless of change in body weight, according to an analysis of the SELECT trial published in The Lancet

The earlier we intervene on the precursor disease of multiple diseases, the less PwO need to suffer from the burdensome sequalae of obesity and the better the quality of life our patients with obesity can have

Delicious chocolate meal replacement with advanced GLP-1 support